Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer’s Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan

Chang, Chien-Chi; Horng, Jorng-Tzong; Hsu, Chi Chang; Chen, Jui Ming

doi:10.1155/2016/9027484

Cited by 25 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These 16 cohort studies including 236,022 participants, published between 1995 and 2016 were identified for analysis on the associations between NSAID use and risk of AD (Breitner et al, 1995 , 2009 ; Stewart et al, 1997 ; in t' Veld et al, 2001 ; Zandi et al, 2002 ; Landi et al, 2003 ; Nilsson et al, 2003 ; Cornelius et al, 2004 ; Arvanitakis et al, 2008 ; Fischer et al, 2008 ; Szekely et al, 2008 ; Ancelin et al, 2012 ; Côté et al, 2012 ; Chang et al, 2016a , b ; Wichmann et al, 2016 ). Characteristics of the included studies are presented in the Table 1 .…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies

Zhang

Wang

et al. 2018

Front. Aging Neurosci.

140

View full text Add to dashboard Cite

Background: Initial observational studies and a systematic review published recently have suggested that non-steroidal anti-inflammatory drug (NSAID) use has the trend to be associated with reduced risk of Alzheimer's disease (AD), while results remain conflicting. Thus, we performed an updated meta-analysis to reevaluate the evidence on this association.Methods: Data sources from PUBMED, Embase and Cochrane Library from inception through April 2017 were searched by two independent reviewers. Eligible cohort studies were selected according to predefined keywords. We did a meta-analysis of available study data using a random-effects model to calculate overall relative risks (RRs) for associations between NSAID exposure and AD risk.Results: From 121 potentially relevant studies, 16 cohort studies including 236,022 participants, published between 1995 and 2016, were included in this systematic review. Meta-analysis demonstrated that current or former NSAID use was significantly associated with reduced risk of AD (RR, 0.81, 95% CI0.70 to 0.94) compared with those who did not use NSAIDs. This association existed in studies including all NSAID types, but not in aspirin (RR, 0.89, 95% CI 0.70 to 1.13), acetaminophen (RR, 0.87, 95% CI 0.40 to 1.91) or non-aspirin NSAID (RR, 0.84, 95% CI 0.58 to 1.23).Conclusions: Current evidence suggests that NSAID exposure might be significantly associated with reduced risk of AD. However, further large-scale prospective studies are needed to reevaluate this association, especially the associations in individual NSAID type.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Several epidemiologic studies showed that patients treated with NSAIDs had a decreased risk for developing AD (Breitner et al, 2009 ; Côté et al, 2012 ; Chang et al, 2016a , b ). However, this evidence was only based on observational studies.…”

Section: Introductionmentioning

confidence: 99%

NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies

Zhang

Wang

et al. 2018

Front. Aging Neurosci.

140

View full text Add to dashboard Cite

show abstract

“…Our research has shown that aspirin, one of world's oldest pharmaceutical agents, exhibits a diverse range of effects in the amelioration AD pathogenesis and subsequent protection of hippocampal neurons (Figure ). Although some studies indicate beneficial role of aspirin in AD (Chang, Horng, Hsu, & Chen, ; Etminan, Gill, & Samii, ; Nilsson et al, ; Wang et al, ), couple of studies contradict such favorable function of aspirin. For instance, Kelley et al () do not find any significant relationship between the daily aspirin use and cognitive change over 2 to 6 years of follow‐up after controlling for the impact of age.…”

Section: Resultsmentioning

confidence: 99%

PPARα serves as a new receptor of aspirin for neuroprotection

Patel

Roy

Pahan

2019

J of Neuroscience Research

View full text Add to dashboard Cite

Acetyl salicylic acid, commonly known as aspirin, has been being widely used as an anti‐inflammatory drug for almost 100 years. However, there was no receptor known for this popular drug. Recently, we have established that peroxisome proliferator‐activated receptor alpha (PPARα) acts as a novel receptor of aspirin. Activation of PPARα by aspirin stimulated a series of downstream signaling pathways that could potentially ameliorate different Alzheimer's disease (AD)‐related pathologies. In this mini‐review, we have discussed how aspirin–PPARα interaction plays a pivotal role in the amelioration of AD pathology via the stimulation of neurotrophic factors, upregulation of plasticity‐associated genes, and removal of plaque burden in hippocampal neurons.

show abstract

“…First, although no distinct mechanisms of statins exist to explain their effects on dementia protection, many studies have discussed their cholesterol-lowering effects and pleiotropic effects, including the beta-amyloid deposition, anti-thrombotic effects, or anti-inflammatory effects of statins related to dementia protection [16,[33][34][35][36]. In addition, since IHD is a well-known risk factor for dementia, anti-hyperlipidemia, anti-platelet, and anti-hypertensive therapy have been suggested to reduce the risk of dementia [37,38]. These findings may help to clarify the beneficial effects of statins on dementia in statin users and non-users with a PS-matched baseline.…”

Section: Discussionmentioning

confidence: 99%

Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease

et al. 2020

View full text Add to dashboard Cite

This study aimed to determine the association between statins and the prevention of dementia according to sex differences in elderly patients with ischemic heart disease (IHD). We performed a nationwide retrospective cohort study using the Korean Health Insurance Review and Assessment Service database (2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015). Among the 264,036 eligible patients aged ≥65 years with IHD, statin users were compared with non-users by propensity score matching at a 1:1 ratio (71,587 in each group). The primary outcome was dementia risk by estimating hazard ratios (HRs) and 95% confidence intervals (CIs). Differential risks of dementia were assessed by sex in the subgroups of statin types, exposure duration, and patient age, implying that sex is an influential factor for the link between statin use and dementia incidence. Among seven commonly prescribed statins, rosuvastatin was associated with the greatest preventive effect on dementia incidence, with an adjusted HR of 0.82 (95% CI = 0.78-0.87). In a subgroup analysis organized by sex, the differential risk of dementia incidence was assessed in each statin group, implying that sex is an influential factor for the link between statin and dementia. This study suggests that appropriate statin use considering sex differences may have beneficial effects on the development of dementia.

show abstract

Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer’s Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan

Cited by 25 publications

References 26 publications

NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies

NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies

PPARα serves as a new receptor of aspirin for neuroprotection

Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease

Contact Info

Product

Resources

About